{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:36:46Z","timestamp":1790750206052,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T00:00:00Z","timestamp":1530921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12149-018-1274-8","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T01:22:57Z","timestamp":1530926577000},"page":"532-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Battistotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rodella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Statuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,7]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10428190802311441","volume":"49","author":"J Rubenstein","year":"2008","unstructured":"Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49:43\u201351.","journal-title":"Leuk Lymphoma"},{"key":"1274_CR2","first-page":"1601","volume":"23","author":"CA Han","year":"2017","unstructured":"Han CA, Batchelor TT. Primary central nervous system lymphoma. Continuum (Minneap Minn). 2017;23:1601\u201318.","journal-title":"Continuum (Minneap Minn)"},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0360-3016(97)00571-3","volume":"41","author":"J Corry","year":"1998","unstructured":"Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41:615\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0360-3016(98)00564-1","volume":"44","author":"N Hayabuchi","year":"1999","unstructured":"Hayabuchi N, Shibamoto Y, Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys. 1999;44:265\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1274_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266\u201372.","journal-title":"J Clin Oncol"},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711\u20135.","journal-title":"J Clin Oncol"},{"key":"1274_CR7","first-page":"1063","volume":"9","author":"KM Braaten","year":"2003","unstructured":"Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063\u20139.","journal-title":"Clin Cancer Res"},{"key":"1274_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353\u20138.","journal-title":"Br J Cancer"},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ana.22360","volume":"70","author":"AF Hottinger","year":"2011","unstructured":"Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, et al. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol. 2011;70:163\u20139.","journal-title":"Ann Neurol"},{"key":"1274_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","volume":"102","author":"M Joerger","year":"2010","unstructured":"Joerger M, Huitema AD, Krahenbuhl S, Schellens JH, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic\u2013pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102:673\u20137.","journal-title":"Br J Cancer"},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/10428194.2010.542261","volume":"52","author":"JA Kim","year":"2011","unstructured":"Kim JA, Kim SJ, Do IG, Jin J, Nam DH, Ko YH, et al. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis? Leuk Lymphoma. 2011;52:205\u201313.","journal-title":"Leuk Lymphoma"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11060-017-2686-3","volume":"136","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Bertoli M, Giubbini R, Bertagna F. 18F-FDG PET\/CT in primary brain lymphoma. J Neurooncol. 2018;136:577\u201383.","journal-title":"J Neurooncol"},{"key":"1274_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12149-014-0851-8","volume":"28","author":"S Yamaguchi","year":"2014","unstructured":"Yamaguchi S, Hirata K, Kobayashi H, Shiga T, Manabe O, Kobayashi K, et al. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Ann Nucl Med. 2014;28:603\u20139.","journal-title":"Ann Nucl Med"},{"key":"1274_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2478\/raon-2013-0016","volume":"47","author":"S Maza","year":"2013","unstructured":"Maza S, Buchert R, Brenner W, Munz DL, Thiel E, Korfel A, et al. Brain and whole-body FDG PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma. Radiol Oncol. 2013;47:103\u201310.","journal-title":"Radiol Oncol"},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/MNM.0000000000000753","volume":"38","author":"NC Purandare","year":"2017","unstructured":"Purandare NC, Puranik A, Shah S, Agrawal A, Gupta T, Moiyadi A, et al. Common malignant brain tumors: can 18F-FDG PET\/CT aid in differentiation? Nucl Med Commun. 2017;38:1109\u201316.","journal-title":"Nucl Med Commun"},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"247152","DOI":"10.1155\/2013\/247152","volume":"2013","author":"N Kawai","year":"2013","unstructured":"Kawai N, Miyake K, Yamamaoto Y, Nishiyama Y, Yamiya T. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. Biomed Res Int. 2013;2013:247152.","journal-title":"Biomed Res Int"},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/BF02985117","volume":"19","author":"N Kawai","year":"2005","unstructured":"Kawai N, Nishiyama Y, Miyake K, Tamiya T, Nagao S. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis. Ann Nucl Med. 2005;19:685\u201390.","journal-title":"Ann Nucl Med"},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00259-005-1917-6","volume":"33","author":"H Palmedo","year":"2006","unstructured":"Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf GH, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging. 2006;33:164\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","volume":"100","author":"N Kawai","year":"2010","unstructured":"Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neurooncol. 2010;100:225\u201332.","journal-title":"J Neurooncol"},{"key":"1274_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2967\/jnumed.112.108654","volume":"54","author":"B Kasenda","year":"2013","unstructured":"Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, et al. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med. 2013;54:184\u201391.","journal-title":"J Nucl Med"},{"key":"1274_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00277-017-3068-9","volume":"96","author":"JC Jo","year":"2017","unstructured":"Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Park JS, et al. Interim 18F-FGD PET\/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Ann Hematol. 2017;96:1509\u201315.","journal-title":"Ann Hematol"},{"key":"1274_CR22","first-page":"9","volume":"37","author":"K Okuyucu","year":"2018","unstructured":"Okuyucu K, Alagoz E, Ince S, Ozaydin S, Arslan N. Can metabolic tumour parameters on primary staging 18F-FDG-PET\/CT contribute to risk stratification of primary central nervous system lymphomas for patient management as a prognostic model? Rev Esp Med Nucl Imagen Mol. 2018;37:9\u201314.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1274_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1274_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00259-006-0153-z","volume":"34","author":"Y Nishiyama","year":"2007","unstructured":"Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging. 2007;34:78\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1274_CR25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s11307-010-0447-1","volume":"13","author":"Y Kawase","year":"2011","unstructured":"Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol. 2011;13:1284\u20139.","journal-title":"Mol Imaging Biol"},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ejca.2014.10.028","volume":"51","author":"P Roth","year":"2015","unstructured":"Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, et al. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer. 2015;51:382\u201390.","journal-title":"Eur J Cancer"},{"key":"1274_CR27","first-page":"368","volume":"14","author":"T Sasayama","year":"2012","unstructured":"Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neurooncology. 2012;14:368\u201380.","journal-title":"Neurooncology"},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","volume":"61","author":"L Nguyen-Them","year":"2016","unstructured":"Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer. 2016;61:69\u201376.","journal-title":"Eur J Cancer"},{"key":"1274_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-015-2470-4","volume":"94","author":"M Madle","year":"2015","unstructured":"Madle M, Kr\u00e4mer I, Lehners N, Schwarzbich M, Wuchter P, Herfarth K, et al. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol. 2015;94:1853\u20137.","journal-title":"Ann Hematol"},{"key":"1274_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/neuonc\/nov046","volume":"17","author":"S Kreher","year":"2015","unstructured":"Kreher S, J\u00f6hrens K, Strehlow F, Martus P, Borowiec K, Radke J, et al. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro Oncol. 2015;17:1016\u201321.","journal-title":"Neuro Oncol"},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nos012","volume":"14","author":"C Colavolpe","year":"2012","unstructured":"Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol. 2012;14:649\u201357.","journal-title":"Neuro Oncol"},{"key":"1274_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2967\/jnumed.111.092387","volume":"53","author":"J Schwarzenberg","year":"2012","unstructured":"Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3\u2032-Deoxy-3\u2032-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29\u201336.","journal-title":"J Nucl Med"},{"key":"1274_CR33","first-page":"1079","volume":"14","author":"RJ Harris","year":"2012","unstructured":"Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, et al. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neurooncology. 2012;14:1079\u201389.","journal-title":"Neurooncology"},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"16822","DOI":"10.18632\/oncotarget.24706","volume":"9","author":"R Birsen","year":"2018","unstructured":"Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, et al. Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients. Oncotarget. 2018;9:16822\u201331.","journal-title":"Oncotarget"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1274-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T19:18:09Z","timestamp":1562440689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,7]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1274-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,7]]},"assertion":[{"value":"8 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}